From CNBC · Natasha Abellard · · 1m 30s
Kimberly-Clark completes Kenvue acquisition
Kimberly-Clark closes $49 billion Kenvue deal, adding Tylenol to portfolio.
In brief
Kimberly-Clark closes $49 billion Kenvue deal, adding Tylenol to portfolio. Kimberly-Clark finalized its $49 billion acquisition of Kenvue, the Tylenol maker, to expand into health and wellness with plans to integrate operations and manage legal risks. Originally reported by CNBC.
Acquisition completion
Kimberly-Clark completed its acquisition of Kenvue, the Tylenol maker, on Monday.
Strategic expansion
The deal broadens Kimberly-Clark's reach into health and wellness as consumers prioritize healthy lifestyles.
Stock performance
Shares rose 0.3% to $108.25 after closing the acquisition at almost $49 billion.
Financial targets
Kimberly-Clark aims for $1.9 billion in cost reductions and $500 million in incremental profits within three years.
Integration challenges
Kimberly-Clark faces questions about integrating Kenvue, managing higher input costs, and handling Tylenol legal issues.
CEO vision
Michael Hsu emphasized strengthening Kenvue's operations and accelerating growth in health products.
Product growth
Hsu noted significant growth potential in Kenvue's product categories including Tylenol, Band-Aid, and Neutrogena.
Inflation management
Kimberly-Clark plans to offset higher input costs while keeping prices affordable for lower-income consumers.
Tylenol legal issues
Tylenol faces litigation over pregnancy use linked to autism and ADHD claims.
Dividend commitment
Kimberly-Clark maintains its dividend aristocrat status with a 4.73% yield and plans to keep dividends safe.
Future outlook
Hsu expects earnings to be accretive by year two and leverage to drop to 2.0 by reducing debt.
The essence
Kimberly-Clark finalized its $49 billion acquisition of Kenvue, the Tylenol maker, to expand into health and wellness with plans to integrate operations and manage legal risks.
